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Breast cancer is the commonest cancer among women in the UK,
with a lifetime risk of almost 1 in 10 (Anderson, 1992). While
familial cancers account for around 5% of all breast cancers, the
remainder appear to be the result of a multifactorial aetiology that
includes a genetic component. Breast cancer is known to be
strongly influenced by the hormonal milieu, and variation in genes
that are responsive to such hormones are therefore possible candi-
dates for increased risk. One potential target is the vitamin D
receptor (VDR), a member of the steroid-hormone family of
nuclear receptors, which are responsible for the transcriptional
regulation of a number of hormone-responsive genes. The vitamin
D receptor (VDR) is expressed in breast tissue, and patients with
VDR-positive breast tumours have longer disease-free survival
compared to those with receptor-negative tumours (Colston et al,
1989). The VDR ligand is the vitamin D metabolite, 1,25 dihy-
droxyvitamin D3 (1,25-D), which has potent effects on cell growth
and differentiation. Laboratory studies have demonstrated that
1,25-D and its analogues inhibit cell proliferation and promote
apoptosis in breast cancer cells in culture (Chouvet et al, 1986;
Eisman et al, 1989; James et al, 1995; Welsh, 1995). In animal
models of breast cancer, vitamin D analogues delay tumour devel-
opment and cause regression of established mammary tumours
(Abe et al, 1991; James et al, 1998). Such evidence has led to the
development of vitamin D analogues as potential new therapeutic
agents (Bower et al, 1991; Gulliford et al, 1998) in breast cancer. 
The gene encoding the VDR is known to contain a number of
polymorphisms. A polymorphic start codon in the 5¢ end of the gene
(identified by the restriction enzyme FokI) results in VDR proteins
that differ in length by 3 amino acids. This polymorphism has been
associated with increased breast cancer risk in African-American
women (Ingles et al, 1997a). 3 sequences in the 3¢ end of the gene
(generating BsmI, ApaI and TaqI restriction sites) are thought to be
linked to a further polymorphism, the variable length poly (A)
sequence in the 3¢ untranslated region (3¢ UTR). Such 3¢UTR
elements are candidate translational control sites, important in the
post-transcriptional control of gene expression (Day and Tuite,
1998). An association between these 3¢ polymorphisms and bone
mineral density has been widely reported (Morrison et al, 1994;
Cooper and Umbach, 1996). They have also been related to a number
of other diseases including prostatic and breast carcinoma: in sepa-
rate US studies, increased risk of prostate cancer has been associated
with a long poly (A) allele (Ingles et al, 1997b), absence of TaqI
(Taylor et al, 1996) and presence of BsmI (Ma et al, 1998) restriction
sites. An association has also been reported between breast cancer
risk and the ApaI polymorphism (Curran et al, 1999), breast cancer
progression and absence of the TaqI polymorphism (Lundin et al,
1999), and BsmI genotype and increased risk of breast metastases
(Ruggiero et al, 1998). These polymorphisms are thought to be in
linkage disequilibrium in Caucasian populations, suggesting they are
essentially looking at the same genotype (Ingles et al, 1997c). 
This study was undertaken to assess whether VDR polymor-
phisms in both the 3¢ and 5¢ end of the gene are associated with
breast cancer risk in a UK Caucasian population. In order to be as
certain as possible that our control group is free of any breast
cancer or precancerous changes that may go undetected in the
general population, women were only recruited following a nega-
tive screening mammogram. 
METHODS 
Subjects 
For both sample groups, written informed consent was obtained 
at the time of interview and sampling. The study was approved by the
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cruitment criteria indicated that volunteers (i) were Caucasian and
(ii) had had a recent mammogram. Women with family history of
breast cancer were not specifically excluded from the study: the
reported incidence was not different between our control and case
groups and showed no relationship with VDR genotype. 
Control volunteers 
Women (n = 241) were recruited through the UK National Breast
Screening Programme for South-West London. This provides for
routine mammography of all women between the ages of 50–65
years at 3 yearly intervals, and 65+ years by self-referral.
Currently, around 5% women screened are recalled to the Unit due
to a technical problem with their mammogram, or for further
investigation. Most of these women are subsequently found to be
healthy and are discharged back into the Screening Programme.
These women therefore have no detectable cancer at time of
sampling, although 89 women had breast conditions not associated
with breast cancer risk (26 had benign calcifications, 26 had fibro-
cystic disease and 37 had a fibroadenoma/other benign lump). The
benign nature of these conditions was confirmed by cytology
and/or radiological stability over time. Because of the nature of the
Screening Programme, control women were in the age range
50–81 years, with a median age of 55.2 years, at the time of
sampling. The age of the control group was therefore different
from the case group. However, there were no age-related differ-
ences in VDR gene frequency between the oldest and youngest
women. The majority of the control group (167 women, 69%)
were postmenopausal and 126 women (52%) were current or past
users of hormone replacement therapy (HRT). 
Breast cancer volunteers 
Women (n = 181) were recruited through the Combined Breast
Clinic at St. George’s Hospital. Women had a median age of 62.1
(range 29.0–91.0) years at the time of sampling. The median age at
diagnosis was 57.2 (range 26.2–89.8) years, with a median time
since diagnosis of 4.3 (range 0.4–27.5) years. Of this group, 149
women (82%) were postmenopausal, and 52 (29%) women were
current/past users of HRT. All women had a surgical procedure
(wide local excision or mastectomy) with or without post-operative
radiotherapy. 
The characteristics of the tumours were confirmed from
histopathological records of core biopsy and/or resection speci-
mens: 20 women had ductal carcinoma-in-situ (DCIS), 70 inva-
sive ductal carcinoma (IDC), 77 both DCIS and IDC, and 14
invasive lobular carcinoma with or without lobular carcinoma in
situ. Tumour grade data was available for 147 patients: 47 (32%)
patients were classed as Bloom and Richardson Grade I, 58 (39%)
patients as Grade II and 42 (29%) patients Grade III. Lymph nodes
were taken from 140 patients. Of these, 108 (77%) had no lymph
node involvement. Oestrogen receptor (ER) levels were deter-
mined for 167 patients, of whom 131 (78%) were ER positive.
Adjuvant tamoxifen was given to 108 women, adjuvant chemo-
therapy to 20 women and a combination of both to 32 women.
Since diagnosis, 21 women have had local recurrence, 3 women
have had new primary breast tumours and 4 have developed
metastatic disease. 
Analysis of VDR polymorphisms 
A 10 ml blood sample was collected into a lithium heparin tube
and used for extraction of DNA (QIAamp blood kit, Quiagen
UK Ltd, W Sussex, England). Genomic DNA was amplified by
PCR using specific primers as previously described (Morrison
et al, 1994; Ingles et al, 1997b; Gross et al, 1998). For BsmI and
FokI genotyping, PCR product was digested with the appro-
priate restriction endonuclease (New England Biolabs UK Ltd,
Hertfordshire, England), separated by agarose gel electrophoresis
and visualized by ethidium bromide staining. For both BsmI and
FokI, genotypes were defined by capital letters in the absence of
the restriction site (B, F respectively) and small letters where the
restriction site was present (b, f ). For the poly (A) analysis, a 425
base pair PCR product was separated on a 6% PAGE-urea gel and
visualized by silver staining (Silver SequenceR, Promega UK,
Southampton, England). Under these conditions, the poly (A)
region resolves into 2 distinct populations, long (L, A18–A24) and
short (S, A13–A17). 
Statistical analysis 
The c2 test was used to assess any association between VDR poly-
morphisms and breast cancer risk. Odds ratios and 95% confi-
dence intervals were calculated to determine the risk of breast
cancer associated with a given VDR genotype using the Clinistat
Programme, devised by Professor Martin Bland, Dept. Public
Health, St George’s Hospital Medical School, London, UK. Allele
frequencies were assessed for deviation from expected Hardy-
Weinberg Equilibrium using the c2 test. 
RESULTS 
The frequency of VDR polymorphisms in our sample populations
are shown in Table 1. We found a highly significant difference in
genotype frequencies between patients and controls, such that the
bb genotype was significantly over-represented in the patient
population (Table 1). The odds of breast cancer for a woman of
genotype bb were twice (OR = 2.32, 95% CI 1.23–4.39, Table 1)
those for a woman of genotype BB. 
The allele frequencies were similar to those reported in other
Caucasian populations (Morrison et al, 1994; Houston et al, 1996;
Harris et al, 1997; Ingles et al, 1997b; Kiel et al, 1997; Vandevyer
et al, 1997; Ferrari et al, 1998). There was slight deviation from
expected Hardy-Weinberg frequencies (P = 0.05) for the BsmI and
poly (A) genotypes, but not the FokI, in the control population
only. Review and checking of our genotyping, including se-
quencing 12 random control DNA samples around the BsmI site
(data not shown), confirmed our genotyping. As the FokI poly-
morphism was in Hardy-Weinberg equilibrium, we suggest that
this result is an anomaly of our sample group. 
The BsmI polymorphism was found to be in strong linkage dis-
equilibrium (410/419 samples genotyped, 98% agreement) with the
variable length poly (A) sequence, such that bb genotype co-segre-
gated with LL long poly (A). Independent analysis of breast cancer
risk associated with the poly (A) genotype were similar to those
associated with BsmI (Table 1). No association was found between
FokI genotype and breast cancer risk (Table 1). The FokI genotype
was not in linkage disequilibrium with the poly (A) polymorphism
(data not shown), suggesting that they segregate independently. 
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associated with particular clinical/pathological characteristics of
our breast cancer group (Table 2). Data is shown only for BsmI
polymorphism, although all 3 genotypes were tested. Due to the
small numbers of BB genotype, for c2 test analysis data were
pooled from BB and  Bb genotypes. There was no association
between any VDR genotype and either ER expression of the
tumour or lymph node involvement. However, there was a signifi-
cant association between the tumour grade and BsmI genotype,
with an excess of bb genotype in those tumours of grades II and
III. Similar results were seen for poly (A) genotype (results not
shown). This suggests that the BsmI/poly (A) is associated with
tumour progression in addition to disease risk. 
DISCUSSION 
We have found a highly significant association between the risk of
breast cancer and the 3¢ VDR gene polymorphisms, BsmI and vari-
able length poly (A) microsatellite, in a UK Caucasian population.
This study has added to the increasing evidence for a role of VDR
gene polymorphisms in the disease process: polymorphisms have
been widely associated with disorders of bone (Morrison et al,
1994; Cooper and Umbach, 1996), and there is increasing
evidence for an association with prostate and breast cancer (Taylor
et al, 1996; Ingles et al, 1997b; Ma et al, 1998; Ruggiero et al,
1998; Curran et al, 1999; Lundin et al, 1999). 
In Caucasian populations, there is thought to be strong linkage
disequilibrium between the 3¢ polymorphisms, BsmI, ApaI, TaqI
and the variable length poly (A), such that only 2 haplotypes are
commonly observed: baTL and BAtS (Morrison et al, 1994; Ingles
et al, 1997c). It is the baTL haplotype that appears to be associated
with increased risk of breast and prostate cancer (Taylor et al,
1996; Ingles et al, 1997b; Ma et al, 1998; Ruggiero et al, 1998;
Curran et al, 1999; Lundin et al, 1999), while the BAtS haplotype is
associated with increased risk of osteoporosis (Morrison et al,
1994; Cooper and Umbach, 1996). Not all studies have shown
such associations: increased breast cancer risk among Latina
women in the United States was associated with SS/BB genotypes
(Ingles et al, 2000), and no association was found between the
VDR TaqI polymorphism and breast cancer risk in Caucasian
women in the UK (Dunning et al, 1999). 
There are difficulties, however, in equating different polymor-
phisms between studies. For example, the strength of linkage dis-
equilibrium can vary significantly between populations (Ingles 
et al, 1997c), resulting in misclassification of the ‘at-risk’ locus. VDR
allele frequencies may also vary within Caucasian populations: of
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Table 1 VDR polymorphism frequencies 
Controls Allele Cases Allele Odds  ratio 
n (%) frequency n (%) frequency (95% confidence interval) 
BsmI c2 test, P = 0.0061** (d.f.=2) 
bb 69 (28.6) b 0.56 78 (43.1)  b 0.66 2.32 (1.23–4.39) 
Bb 133 (55.2) B 0.44 84 (46.4)  B 0.34 1.30 (0.70–2.39) 
BB 39 (16.2) 19 (10.5) 1.0 
Poly A c2 test, P = 0.0068** (d.f.=2) 
LL 67 (28.2) L 0.56 76 (42.0) L 0.66  2.46 (1.29–4.70) 
LS 132 (55.5) S 0.44 87 (48.1) S 0.34  1.43 (0.77–2.66) 
SS 39 (16.4) 18 (9.9) 1.0 
FokI c2 test, P = 0.68 (d.f.=2) 
FF 86 (35.7) F 0.60 72 (39.8)  F 0.62 1.17 (0.65–2.08) 
Ff 116 (48.1) f 0.40 81 (44.8)  f 0.38 0.97 (0.55–1.71) 
ff 39 (16.2) 28 (15.5) 1.0 
** statistically significant. d.f. = degrees of freedom. 
Table 2 Further analysis of cancer group in relation to BsmI genotype 
Risk factor c2 test 
for BsmI genotype 
ER status of tumour ER+ve ER–ve 
bb 59 14 c2 test, P = 0.51 (d.f.=1) 
Bb/BB 72 22
total 131 36 
Lymph node involvement Node –ve Node+ve 
bb 45 15 c2 test, P = 0.60 (d.f.=1) 
Bb/BB 63 17
total 108 32 
Tumour Grade Grade I Grade II Grade III
bb 15 32 16 c2 test, P = 0.043* (d.f.=2) 
Bb/BB 32 26 26
total 47 58 42 
* statistically significant. d.f. = degrees of freedom.10 polymorphic genes assessed in a Finnish study, the prevalence
of the 3¢ TaqI polymorphism was significantly different from other
Caucasian populations (Woodson et al, 1999). That the Caucasian
population is heterogeneous with respect to the VDR gene is one
possible explanation for such discrepancies between population-
based VDR association studies. 
Another difficulty with VDR polymorphisms studies is that, to
date, no clearly defined functional effect of the different geno-
types has been demonstrated. The BB genotype has been associ-
ated with elevated serum calcitriol levels (Morrison et al, 1994;
Ma et al, 1998), and the BAt haplotype shown to have increased
activity in a reporter gene assay (Morrison et al, 1994). There 
has been no conclusive demonstration of any genotype associa-
tion with VDR mRNA levels: no effect (Mocharla et al, 1997;
Gross et al, 1998), decreased (Carling et al, 1998) and increased
(Verbeek et al, 1997) expression of mRNA have all been
reported. 
One problem is the nature of the polymorphisms: the BsmI and
ApaI polymorphisms are intronic, while TaqI leads to a silent
codon change. As such, they do not apparently lead to any change
in either the transcribed mRNA or translated protein. It has been
suggested that they are markers for the poly (A) sequence: such
elements in the 3¢ UTR of genes are thought to be important in
post-transcriptional control of gene expression (Day and Tuite,
1998), either by altering mRNA stability or the interaction of the
mRNA with the translational apparatus. There has been no
evidence to date, however, that the poly (A) element has such a
role – attempts to demonstrate an effect on mRNA stability were
negative (Durrin et al, 1999). Further work is clearly necessary to
try and identify functional mechanisms for the observed effects of
the VDR polymorphisms. 
Finally, while VDR polymorphisms may influence disease
risk, such genetic factors cannot be dissociated from environ-
mental influences. Breast cancer is strongly influenced by
hormonal factors, in particular oestrogen. We found no associa-
tion between VDR genotype and ER status in our group of
largely post-menopausal women. In contrast, Lundin et al (1999)
found a trend towards increased survival in ER-positive, pre-
menopausal women possessing the tt genotype. However, the
relationship between VDR polymorphisms and breast cancer risk
may be very different in pre- and post-menopausal women.
Dietary influences may also be important in modulating risk: bb
genotype has been associated with increased prostate cancer in
elderly men who are also deficient in vitamin D (Ma et al, 1998).
It would be interesting to determine the extent of vitamin D defi-
ciency in conjunction with VDR polymorphisms and breast
cancer risk. 
In conclusion, this study has provided additional support for a
significant association between VDR gene polymorphisms and the
risk of breast cancer. The potent actions of vitamin D and its
analogues as anti-proliferative and pro-differentiation agents in
breast cancers (Chouvet et al, 1986; Eisman et al, 1989; Abe et al,
1991; James et al, 1995; Welsh, 1995; James et al, 1998) have led
to the suggestion that endogenous levels of active vitamin D are a
factor in the development and progression of breast cancers.
However, the ability of 1,25-D to act at the cellular level will be
influenced by levels and activity of the VDR. While vitamin D and
its analogues are being developed as preventative and/or treatment
agents in breast cancer, the assessment of VDR polymorphisms
may be vital in the identification of at-risk groups and strategies
for targeting and intervention. 
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